By Fineline Cube 
Hotgen Biotech (SHA: 688068) has officially registered Beijing Shangjing Zhiyao Technology Co., Ltd., a wholly-owned subsidiary dedicated to advancing artificial intelligence applications in the design and development of small nucleic acid therapeutics. The move represents a strategic expansion of Hotgen’s computational drug discovery capabilities through its X-Gen AI Novel Drug Discovery and Design Research Center.
Corporate Structure & Investment
| Item | Detail |
|---|---|
| Parent Company | Hotgen Biotech (SHA: 688068) |
| New Entity | Beijing Shangjing Zhiyao Technology Co., Ltd. |
| Establishment Date | June 2026 |
| Registered Capital | RMB 20 million |
| Ownership | 100% wholly-owned subsidiary |
| Strategic Focus | Full-process AI application in small nucleic acid drug R&D |
Technology Platform & Innovation Strategy
- Core Asset: X-Gen AI Novel Drug Discovery and Design Research Center
- Primary Objective: Restructure the R&D paradigm for small nucleic acid drugs using artificial intelligence
- Platform Vision: Build an intelligent drug discovery platform that accelerates pipeline development
- Research Scope: Empower both small nucleic acid drug discovery and translational medicine research
- Investment Direction: Continuous increase in AI technology investment within innovative drug business sector
Strategic Rationale & Market Positioning
| Aspect | Details |
|---|---|
| Industry Trend | Growing convergence of AI and pharmaceutical R&D, particularly in nucleic acid therapeutics |
| Competitive Advantage | End-to-end AI integration across the entire small nucleic acid drug development lifecycle |
| Technology Differentiation | Leveraging proprietary AI models specifically trained on nucleic acid chemistry and biological interactions |
| Development Efficiency | Expected reduction in preclinical timeline by 30–40% compared to traditional approaches |
| Pipeline Impact | Accelerated intelligent upgrade of Hotgen’s existing small nucleic acid drug candidates |
Forward Outlook
Beijing Shangjing Zhiyao’s establishment positions Hotgen Biotech at the forefront of China’s emerging AI-pharmaceutical innovation ecosystem. By focusing exclusively on small nucleic acid therapeutics—a rapidly growing segment with significant potential in precision medicine—the subsidiary aims to address critical bottlenecks in target identification, molecular design, and delivery optimization through machine learning algorithms and computational biology.
The company plans to integrate multi-omics data with structural biology insights to enhance prediction accuracy for nucleic acid drug candidates, potentially reducing clinical failure rates and accelerating time-to-market for novel therapeutics.
Forward-Looking Statements
This brief contains forward-looking statements regarding Hotgen Biotech’s strategic initiatives, technological capabilities, and development timelines. Actual results may differ due to risks including technological implementation challenges, regulatory requirements, and competitive dynamics in the AI-driven drug discovery space.-Fineline Info & Tech